<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874315</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000636111</org_study_id>
    <secondary_id>NCH-08-0234</secondary_id>
    <secondary_id>IRB-2008-0230</secondary_id>
    <nct_id>NCT00874315</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.</brief_title>
  <official_title>A Multicenter Pilot Study of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation With In-vivo T-cell Depletion to Evaluate the Role of NK Cells and KIR Mis-matches in Relapsed or Refractory High-risk Neuroblastoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor prognosis and&#xD;
      children with relapsed NBL have an overall 3 year survival rate of &lt; 10%. Hematopoietic Stem&#xD;
      Cell Transplant from a different donor (allogeneic), is a form of adoptive cellular therapy ,&#xD;
      such that infused donor cells find host tumors as foreign and fight them. After transplant,&#xD;
      the donor immune cells (i.e. T cells, NK cells) mediate Graft versus Tumor (GVT) effect and&#xD;
      may stop tumor from recurring. Also,reduced intensity transplants lead to minimal toxicity&#xD;
      and less risk of mortality in heavily pre-treated NBL patients.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving a reduced intensity(using&#xD;
      Fludarabine, Busulfan and antithymocyte globulin)preparative regimen followed by donor stem&#xD;
      cell transplant works in treating young patients with high-risk neuroblastoma that has&#xD;
      relapsed or not responded to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the feasibility of allogeneic hematopoietic stem cell transplantation after&#xD;
           a reduced-intensity conditioning regimen comprising fludarabine phosphate, busulfan, and&#xD;
           anti-thymocyte globulin, in terms of donor engraftment, transplant-related mortality,&#xD;
           and development of acute and chronic graft-vs-host disease, in pediatric patients with&#xD;
           high-risk relapsed or refractory neuroblastoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To elucidate the role of natural killer (NK) cells as effectors of graft-vs-tumor effect&#xD;
           in these patients.&#xD;
&#xD;
        -  To evaluate the role of killer immunoglobulin-like receptor (KIR) mismatches in the&#xD;
           donor-recipient pairs on the outcomes of these patients.&#xD;
&#xD;
        -  To determine the incidence of progression-free survival at 1 year post-transplantation&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Reduced-intensity conditioning regimen: Patients receive fludarabine phosphate IV over 1&#xD;
           hour on days -10 to -6, busulfan IV over 2 hours once on day -10 (test dose) and then&#xD;
           every 6 hours on days -5 and -4, and anti-thymocyte globulin IV over 6-8 hours on days&#xD;
           -3 to -1 and on day 2.&#xD;
&#xD;
        -  Transplantation: Patients undergo allogeneic bone marrow or G-CSF-mobilized peripheral&#xD;
           blood stem cell transplantation on day 0.&#xD;
&#xD;
        -  Graft-vs-host disease (GVHD) prophylaxis: Patients receive cyclosporine or tacrolimus IV&#xD;
           or orally beginning on day -2 and continuing until day 60 or day 100, followed by a&#xD;
           taper until day 100 or day 180 in the absence of GVHD. Patients also receive&#xD;
           mycophenolate mofetil IV or orally on days 1-30, followed by a taper until day 60 in the&#xD;
           absence of GVHD.&#xD;
&#xD;
      Blood samples are collected at baseline and on days 30, 60, and 100 for correlative&#xD;
      laboratory studies. Samples are analyzed for killer immunoglobulin-like receptor (KIR)&#xD;
      mismatches by genotyping and immunophenotyping methods (PCR and flow cytometry); natural&#xD;
      killer (NK) cell reconstitution by flow cytometry; and NK cell function, NK cell&#xD;
      allo-reactivity by ELISPOT and ELISA.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of accrual&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility as measured by the incidence of donor engraftment, transplant-related mortality, and grade III-IV acute graft-vs-host disease (GVHD) at day 100 and the incidence of extensive chronic GVHD within the first year post-transplantation</measure>
    <time_frame>100 days post-HSCT</time_frame>
    <description>The safety and feasibility of reduced intensity allogeneic HSCT will be established in this population by monitoring the incidence of adverse events- 100 day mortality,incidence of severe acute GVHD and non-engraftment of donor cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) at 1 year</measure>
    <time_frame>1 year post- HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between biologic endpoints (e.g., number of natural killer [NK] cells infused, NK cell recovery, and NK cell chimerism status) and clinical endpoints (e.g., donor engraftment, acute GVHD, transplant-related mortality, and PFS)</measure>
    <time_frame>3 and 6 months post-SCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between presence of killer immunoglobulin-like receptor (KIR) mismatches and clinical endpoints</measure>
    <time_frame>3 and 6 months post-HSCT</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.</description>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>0.8 mg/kg/dose for total of 8 doses.</description>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>1.5 mg/kg/dose every 12 hours.</description>
    <other_name>Sandimmune, Gengraf, Neoral.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>30 mg/m2/day for 5 days.</description>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>15 mg/kg/dose every 8 hours</description>
    <other_name>Cell-cept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>0.03 mg/kg/day as continuous infusion or 12 hour divided doses</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of high-risk neuroblastoma, meeting one of the following criteria:&#xD;
&#xD;
               -  Refractory disease, defined as no response, mixed response, or progressive&#xD;
                  disease after completion of induction therapy administered according to clinical&#xD;
                  trials COG-A3973 or COG-ANBL0532 (or other similar high-intensity induction&#xD;
                  regimen)&#xD;
&#xD;
               -  Relapsed following high-dose chemoradiotherapy including autologous stem cell&#xD;
                  transplantation&#xD;
&#xD;
          -  Achieved a complete remission (CR), very good partial remission (VGPR), or partial&#xD;
             remission (PR) after â‰¤ 2 different salvage regimens, as defined by the following:&#xD;
&#xD;
               -  In CR after treatment with some form of salvage therapy (e.g., Â¹Â³Â¹I-MIBG,&#xD;
                  antibody-based therapy, or any other COG or NANT salvage-therapy regimen)&#xD;
&#xD;
               -  In VGPR or PR after salvage therapy&#xD;
&#xD;
                    -  No more than 3 sites of skeletal disease as determined by an Â¹Â²Â³I-MIBG scan&#xD;
                       (for regional involvement of the skeleton [e.g., pelvis, spine], the tumor&#xD;
                       involvement should be &lt; 25% of the site)&#xD;
&#xD;
                    -  Bone marrow involvement (&lt; 25% neuroblasts) by morphologic exam within the&#xD;
                       past 2 weeks&#xD;
&#xD;
                    -  Patients with soft tissue disease are eligible provided they exhibit either&#xD;
                       a VGPR or PR in the primary soft tissue mass and in any sites of metastatic&#xD;
                       soft tissue disease&#xD;
&#xD;
          -  Disease status meeting one of the following criteria:&#xD;
&#xD;
               -  Minimal residual disease&#xD;
&#xD;
               -  Disease considered responsive to a salvage regimen&#xD;
&#xD;
               -  Stable disease&#xD;
&#xD;
          -  No rapidly progressive disease&#xD;
&#xD;
          -  Donors must meet one of the following criteria:&#xD;
&#xD;
               -  Matched, related donor (6/6 or 5/6) (bone marrow donor allowed)&#xD;
&#xD;
               -  HLA-matched unrelated donor (10/10 match on high-resolution [HR] typing of HLA-A,&#xD;
                  B, C, DRB1, and DQB1)&#xD;
&#xD;
               -  One allele- or antigen-mismatched unrelated donor (9/10 match on HR typing),&#xD;
                  mismatched at HLA-C only&#xD;
&#xD;
               -  One allele- or antigen-mismatched unrelated donor (9/10 match on HR typing),&#xD;
                  mismatched at HLA-A, B, DRB1, or DQB1 (only when HLA-C mismatch is not available)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky/Lansky performance status 60-100%&#xD;
&#xD;
          -  ANC &gt; 500/mm^3&#xD;
&#xD;
          -  Creatinine clearance or radioisotope GFR â‰¥ 60 mL/min&#xD;
&#xD;
          -  Total bilirubin &lt; 3.0 mg/dL&#xD;
&#xD;
          -  AST or ALT &lt; 5 times upper limit of normal&#xD;
&#xD;
          -  Shortening fraction â‰¥ 25% by ECHO OR ejection fraction &gt; 30% by MUGA&#xD;
&#xD;
          -  FEV_1 and DLCO â‰¥ 30% OR normal chest x-ray, pulse oximetry, and venous blood gas&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active or recent (within the past 30 days) fungal infection&#xD;
&#xD;
          -  No proven or suspected sepsis, pneumonia, or meningitis unless appropriate therapeutic&#xD;
             measures have been initiated to control the infection and systemic signs are no longer&#xD;
             life-threatening&#xD;
&#xD;
          -  No requirement for oxygen or ventilator support&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior tandem autologous stem cell transplantations (according to clinical trial&#xD;
             COG-ANBL0532) allowed&#xD;
&#xD;
          -  No prior allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  More than 2 months since prior autologous stem cell transplantation, myeloablative&#xD;
             therapy, total-body irradiation, whole abdominal radiotherapy, or therapeutic&#xD;
             Â¹Â³Â¹I-MIBG&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy, immunotherapy (including anti-GD2&#xD;
             regimen), or biologic response modifiers and recovered&#xD;
&#xD;
          -  More than 2 weeks since prior local radiotherapy to the sites of metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Soni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital of NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hopsital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent or refractory neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

